VKTXNASDAQ

Viking Therapeutics

Viking Therapeutics, Inc. · San Diego, CA · founded 2012

Viking Therapeutics is a clinical-stage biotech in San Diego developing oral and injectable drugs for metabolic disease. Its lead program, VK2735, is a dual GLP-1 / GIP receptor agonist that mimics two gut hormones to drive weight loss; the company is testing both subcutaneous and oral formulations as competitors to semaglutide and tirzepatide. A second program, VK2809, targets a thyroid hormone receptor in the liver to reduce fat in MASH (formerly NASH).

Lead asset: dapiglutide · Ph3 · Obesity; peptide · dual GLP-1 / GIP receptor agonist
Pipeline: 1 drug · 1 program; 1 Obesity / GLP-1
Modalities: peptide×1

FocusObesity / GLP-1NASH / MASH

Last refresh · 2mo ago · 10-K

$38.00+23.26%1Y

VKTX · daily close · illustrative · 1 catalyst marked

Conf.+8%

1Y high$38.771Y low$29.39range$9.38(32%)past catalysts

Peers in this space

same sector or modality · sorted by match strength + market cap

RYTM$3.9B

Rhythm Pharmaceuticals

Rel.

0.32

Obesity / GLP-1peptide

2 programsmatch: sector + modality

1 programmatch: modality

Pipeline & catalysts

1 drug · 1 programs · 2 upcoming catalysts

Pipeline by phase1programs

Preclin0
Ph10
Ph20
Ph31
Filed0
Approved0

dapiglutide

dapiglutide (VK2735)

peptidedual GLP-1 / GIP receptor agonist

Obesity

Phase 3

1 program·1 trial·View drug →

Upcoming catalysts2

Conf.MAY–MAY2026·30 daysWINDOW

Dapiglutide Oral Phase 1b Cardiometabolic Data — ADA 2026

Phase 1b cardiometabolic biomarker data for oral dapiglutide at ADA 2026. Closest oral GLP-1 comparator in development: Lilly’s orforglipron. Watch: weight change, A1c, fasting glucose, GI tolerability at oral exposure levels.

Cited“Phase 1b cardiometabolic biomarker data for the oral formulation of dapiglutide will be presented at the American Diabetes Association Scientific Sessions (May 30 – June 2, 2026).”

Conference Data·8-K·disclosed 2mo ago

ReadoutQ3'26·4 monthsQTR

Dapiglutide VENTURE-3 Topline (Phase 3 Obesity)

Phase 3 weight-loss trial of Viking’s dual GLP-1 / GIP injectable in obese adults. Comparators in the same class: tirzepatide ~21% mean weight loss at 72 weeks; semaglutide ~15% at 68 weeks. Watch: % body-weight reduction at primary endpoint, GI tolerability, discontinuation rate.

Cited“Following the completion of additional enrollment cohorts, the Company now expects to report VENTURE-3 topline data in the second half of 2026, with results most likely in the fourth quarter.”

Topline Readout·8-K·disclosed 2mo ago·NCT06049498n=4,500

Past catalyst impact

4 historical events · % change vs announcement

DateKindEventOutcome+1W+1M+6M

Nov 26, 2025Conf.dapiglutide — ASH Late-Breaker — Updated SurvivalPositive+8.2%+4.3%+6.6%

Jan 30, 2025Enroll.dapiglutide — Pivotal Enrollment CompletePositive+3.2%+4.3%+2.6%

Apr 5, 2024PDUFAdapiglutide — PDUFA — ApprovedPositive+36.8%+23.9%+28.5%

Nov 7, 2023Interimdapiglutide — Phase 3 Interim — Stopped for EfficacyPositive+8.6%+15.3%+8.2%

% change vs ticker close on the announcement date · backtest illustrative

Smart money

Insider activity

SEC EDGAR Form 4 · last 90 days

Insider activity · last 90 days

Form 4 trail · 7 transactions · 7 insiders

3 near a catalyst

Net flow

+$3.4M

Buys

$3.6M

5 txns

Sells

$259.1K

1 txns

Largest

+$1.7M

CFO buy

Net flow per quarter · last 8Q

11 txns · sum +$3.32M

24Q324Q425Q125Q225Q325Q426Q126Q2

buys · $4.13Msells · $804K

Insider · roleActionSharesPriceValueDate

B. Mendoza

CFO

Buy52,629$31.54+$1.7M

Apr 23, 2026

37d to catalyst

T. Müller

CSO

Buy21,358$38.27+$817.3K

Apr 23, 2026

37d to catalyst

E. Müller

Chair

Option ex.5,443$28.47$155.0K

Apr 13, 2026

A. Goldstein

Director

Buy1,959$33.27+$65.2K

Mar 19, 2026

M. Kowalski

SVP

Buy7,174$33.36+$239.3K

Mar 6, 2026

J. Hassan

SVP

Buy23,460$35.84+$840.9K

Feb 21, 2026

C. Walsh

EVP

Sell8,911$29.08−$259.1K

Feb 5, 2026

Congressional trading

STOCK Act PTRs · House & Senate

Congressional trading · STOCK Act · last 365d

8 trades · 5 members

2 near a catalyst

Est. net flow

−$1.27M

midpoint · brackets only

Buys

Sells

Party mix

6 D2 R

Member · chamberActionBracket~ midpointOwnerDate · disclosure

Rep. P. Bowen

House · NJ

Buy$15K–$50K~$33Kdependent

Mar 19, 2026

filed +44d

72d to catalyst

Rep. K. Linville

House · WA

Partial sell$15K–$50K~$33Kself

Mar 2, 2026

filed +7d

89d to catalyst

Rep. H. Patel

House · IL

Buy$1.00M–$5.00M~$3.00Mself

Dec 7, 2025

filed +28d

Sen. A. Reyes

Senate · CA

Sell$250K–$500K~$375Kdependent

Jul 31, 2025

filed +2d

Rep. K. Linville

House · WA

Buy$15K–$50K~$33Kspouse

Jun 27, 2025

filed +12d

Rep. J. Calhoun

House · GA

Sell$500K–$1.00M~$750Kjoint

Jun 24, 2025

filed +37d

Rep. H. Patel

House · IL

Sell$100K–$250K~$175Kself

Jun 14, 2025

filed +24d

Rep. J. Calhoun

House · GA

Sell$1.00M–$5.00M~$3.00Mspouse

May 24, 2025

filed +37d

Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value

Top ETF holders

ETF NAV disclosures · 13F filings

ETF holders · NAV disclosures

5 ETFs hold the position

Held by ETFs

$29.5M

aggregate position

Of market cap

0.70%

aggregate ETF share

Top holder

IBB0.18%

iShares Biotechnology ETF

TickerETF · familyThemeNAV% of NAVPosition

IBB

iShares Biotechnology ETF

iShares

Broad biotech$8.40B0.18%$15.1M

XBI

SPDR S&P Biotech ETF

SPDR

Broad biotech$7.90B0.13%$10.3M

SBIO

ALPS Medical Breakthroughs ETF

First Trust

Small-cap biotech$110.0M1.74%$1.9M

BBC

Virtus LifeSci Biotech Clinical Trials

WisdomTree

Small-cap biotech$60.0M2.52%$1.5M

PBE

Invesco Dynamic Biotechnology

Invesco

Broad biotech$175.0M0.37%$648K

Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund

KOL network

CMS OpenPayments · 2024 – 2025

KOL network · CMS OpenPayments

12 physicians paid · 52 disclosed records

Total 2025+2024

$2.73M

YoY

+31%

Research Grant$1.08MCo-Investigator$1.05MEquity / Ownership$316.8KConsulting$128.8KSpeaking$122.1KTravel & Lodging$33.3KFood & Beverage$1.9K

Physician · affiliationSpecialtyTop categoryTotalRecords

Dr. Sarah O'Connor

Johns Hopkins

GastroenterologyCo-Investigator$696.8K7

Dr. Charles Chen

Stanford Medicine

HepatologyCo-Investigator$615.4K6

Dr. Maya Greene

Duke University

HepatologyResearch Grant$403.2K7

Dr. James Davies

MD Anderson

HepatologyResearch Grant$345.4K7

Dr. Ahmed Romano

University of Michigan

GastroenterologyCo-Investigator$138.1K2

Dr. Henry Nakamura

Memorial Sloan Kettering

HepatologyEquity / Ownership$118.1K5

Dr. Henry Müller

Vanderbilt

HepatologyConsulting$102.2K5

Dr. Kavya Müller

Johns Hopkins

HepatologyResearch Grant$99.4K5

Dr. Nadia Chen

Cleveland Clinic

HepatologyResearch Grant$89.0K2

Dr. Charles Goldstein

Mayo Clinic

HepatologyEquity / Ownership$74.4K2

Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs

Government & IP

Federal lobbying

Senate LDA disclosures · last 8 quarters

Federal lobbying · LDA · last 8 quarters

$814K disclosed · 2 firms engaged

YoY change

+31%

last 4Q vs prior 4Q

24Q3Q425Q1Q2Q3Q426Q1Q2

Top lobbying firms · last 8Q

Mehlman Castagnetti$482K

7 quarters active

Tiber Creek Group$332K

5 quarters active

Top issues lobbied

FDA user fee reauthorization (PDUFA / BsUFA)$332K
Sunshine Act expansion$161K
GLP-1 coverage under Medicare Part D$161K
Inflation Reduction Act drug-price negotiation$161K

Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed

Government contracts

USAspending.gov · BARDA · NIH · DoD · HHS · VA

Federal contracts · USAspending.gov

2 awards · 2 agencies

Total awarded

$33.1M

across all programs

Active

$33.1M

option periods incl.

Top agency

NIH / NIAID$30.2M

largest active: Antiviral Drug Discovery Cooperative

AgencyTitle · type · award IDStatusValueAwarded → ends

NIH / NICHD

Pediatric Rare Disease Natural History Study

Grant · NIH-92002695

active$2.9MDec 2025→ Feb 2027

NIH / NIAID

Antiviral Drug Discovery Cooperative

Cooperative Agreement · NIH-53170414

active$30.2MMay 2025→ Sep 2028

Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)

U.S. Patents

USPTO PEDS & Patent Public Search

U.S. Patents · USPTO

5 granted · 2 pending

Total in portfolio

Granted in last 12mo

Expiring < 2yr

Nearest expiry

Apr 2031

Patent #Title · inventor · drugTypeStatus · filedExpiry

12,258,021

Genome editing constructs encoding dapiglutide

J. Walsh + 2 · dapiglutide

Composition of Matter

grantedfiled Apr 2026

exp. Apr 2046

20.0y left

11,750,944

Bispecific antibody compositions targeting dapiglutide

M. Müller + 4 · dapiglutide

Composition of Matter

grantedfiled Apr 2025

exp. Apr 2045

19.0y left

12,200,698

Small molecule modulators of dapiglutide

L. Iyer + 1 · dapiglutide

Composition of Matter

grantedfiled Apr 2024

exp. Apr 2044

18.0y left

US 2026/2388471 A1

Dosing regimens for chronic administration of dapiglutide

M. Reyes · dapiglutide

Method of Use

pendingfiled Apr 2026

in prosecution

US 2025/4771921 A1

Methods of stratifying patients for treatment with dapiglutide

T. Andersson + 3 · dapiglutide

Method of Use

pendingfiled Apr 2025

in prosecution

11,665,885

Small molecule modulators of dapiglutide

A. Kowalski + 2 · dapiglutide

Composition of Matter

grantedfiled Apr 2013

exp. Apr 2033

7.0y left

11,629,507

Lipid nanoparticle formulations comprising dapiglutide

A. Romano + 1 · dapiglutide

Composition of Matter

grantedfiled Apr 2011

exp. Apr 2031

5.0y left

Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing

News

PR wires · biotech trades · company IR · last 90 days

News · last 90 days

10 items from 4 categories

clinical5regulatory3partnership1corporate1

just now

EMA validates VKTX's Marketing Authorization Application for dapiglutide

Endpoints News$·regulatory

1d ago

VKTX closes ex-U.S. rights deal worth $1.3 billion in milestones

PR Newswire·partnership

6d ago

VKTX receives Orphan Drug Designation for dapiglutide

Endpoints News$·regulatory

10d ago

VKTX provides corporate update at investor conference

Business Wire·corporate

21d ago

VKTX presents dapiglutide data at major medical conference

PR Newswire·clinical

22d ago

VKTX completes enrollment in dapiglutide Phase 2 trial

Endpoints News$·clinical

1mo ago

VKTX announces interim analysis from dapiglutide pivotal study

FierceBiotech·clinical

1mo ago

VKTX doses first patient in Phase 3 dapiglutide study

Endpoints News$·clinical

2mo ago

FDA accepts VKTX's NDA for dapiglutide; PDUFA date set

PR Newswire·regulatory

3mo ago

VKTX reports topline results from Phase 2 trial of dapiglutide

Endpoints News$·clinical

Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline

Financials

snapshot · sourced to filings · refreshed at next 10-Q

Trading

Previous close

$38.00

Open

$38.00

Day Δ

+0.00

+0.00%

Day range

$37.72 – $38.28

52W range

$29.39 – $38.77

Avg daily volume

1.50M

Valuation & ownership

Enterprise value

$3.7B

Shares out

110.53M

Float

103.90M

Insider %

12.93%

Institutional %

72.93%

Beta

1.93

vs SPY · 52w

Balance sheet & burn

Cash + invest

$1.1B

Total debt

$193M

Debt / equity

7.93

Cash burn / Q

$64M

R&D spend TTM

$243M

23% of cash

ATM available

None

no active facility

Earnings

EPS latest

$-0.68

EPS Δ vs prior

+0.13

EPS estimate

$-0.75

next quarter

EPS prior

$-0.81

Next earnings

May 21, 2026

Rev guidance

$34M

All values reflect the most recent 10-Q / 10-K filing or seeded equivalent. Beta, IV, short interest, and borrow availability are derived from broker-feed conventions. Upgrade to Pro for live updates.

Recent disclosure activity

last 3 observations

2mo agodapiglutideDapiglutide VENTURE-3 Topline (Phase 3 Obesity)High10-K

2mo agodapiglutideDapiglutide VENTURE-3 Topline (Phase 3 Obesity)High8-K

2mo agodapiglutideDapiglutide Oral Phase 1b Cardiometabolic Data — ADA 2026High8-K